Cargando…

Current status and challenges of immunotherapy in ALK rearranged NSCLC

Rearrangements of the anaplastic lymphoma kinase (ALK) gene account for 5-6% in non-small cell lung cancer (NSCLC). ALK rearranged NSCLC is sensitive to ALK tyrosine kinase inhibitors (TKIs) but prone to drug resistance. Meanwhile, ALK rearranged NSCLC has poor response to single immunotherapy. Here...

Descripción completa

Detalles Bibliográficos
Autores principales:	Qi, Rongbin, Yu, Yingying, Shen, Mo, Lv, Dongqing, He, Susu
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2022
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9795041/ https://www.ncbi.nlm.nih.gov/pubmed/36591504 http://dx.doi.org/10.3389/fonc.2022.1016869

Ejemplares similares

Targeting ALK Rearrangements in NSCLC: Current State of the Art
por: Peng, Ling, et al.
Publicado: (2022)

ALK Inhibitors in the Treatment of ALK Positive NSCLC
por: Khan, Muhammad, et al.
Publicado: (2019)

Case Report: Keratoacanthoma and type I diabetes secondary to treatment with PM8001, a bifunctional fusion protein targeting TGF-β and PD-L1
por: Qi, Rongbin, et al.
Publicado: (2023)

Characterization With KRAS Mutant Is a Critical Determinant in Immunotherapy and Other Multiple Therapies for Non-Small Cell Lung Cancer
por: Shen, Mo, et al.
Publicado: (2022)

Case report: Durable response to alectinib in ALK-rearranged lung adenocarcinoma with acquired, crizotinib-resistant ALK C1156F mutation
por: Rao, Chuangzhou, et al.
Publicado: (2022)

Immunotherapy in the First-Line Treatment of NSCLC: Current Status and Future Directions in China
por: Xiong, Anwen, et al.
Publicado: (2021)

Feasibility and Challenges for Sequential Treatments in ALK-Rearranged Non-Small-Cell Lung Cancer
por: Elsayed, Mei, et al.
Publicado: (2021)

The Genomic Characteristics of ALK Fusion Positive Tumors in Chinese NSCLC Patients
por: Liu, Shaokun, et al.
Publicado: (2020)

ALK-Rearranged NSCLC With Concomitant HER2-Mutant Breast Cancer Patient Treated With Alectinib, Trastuzumab, and Pertuzumab: A Case Report
por: Takayasu, Hirokazu, et al.
Publicado: (2023)

A Screening Method for the ALK Fusion Gene in NSCLC
por: Murakami, Yoshiko, et al.
Publicado: (2012)

RT-based combination therapy for brain metastasis from NSCLC with non-EGFR mutation/ALK gene rearrangement: A network meta-analysis
por: Wu, Min, et al.
Publicado: (2022)

Multiple Primary Lung Cancers With ALK Rearrangement: A Case Report and Literature Review
por: Huimin, Zhou, et al.
Publicado: (2022)

ALK‐rearrangement in non‐small‐cell lung cancer (NSCLC)
por: Du, Xue, et al.
Publicado: (2018)

Successful Treatment of a Resistant Subclone in ALK-Rearranged NSCLC
por: König, David, et al.
Publicado: (2020)

Management of Oligoprogression in Patients with Metastatic NSCLC Harboring ALK Rearrangements
por: Pisano, Chiara, et al.
Publicado: (2022)

Monomerization of ALK Fusion Proteins as a Therapeutic Strategy in ALK-Rearranged Non-small Cell Lung Cancers
por: Hirai, Noriko, et al.
Publicado: (2020)

Concomitant EGFR Mutations and ALK Rearrangements in Lung Adenocarcinoma Treated With Osimertinib
por: Thomas, David, et al.
Publicado: (2023)

ALK Rearrangement–Positive Pancreatic Cancer with Brain Metastasis Has Remarkable Response to ALK Inhibitors: A Case Report
por: Ou, Kai, et al.
Publicado: (2021)

Biomarkers for Immunotherapy of Oral Squamous Cell Carcinoma: Current Status and Challenges
por: Almangush, Alhadi, et al.
Publicado: (2021)

A Machine Learning Model Based on PET/CT Radiomics and Clinical Characteristics Predicts ALK Rearrangement Status in Lung Adenocarcinoma
por: Chang, Cheng, et al.
Publicado: (2021)

Changing ALK-TKI-Resistance Mechanisms in Rebiopsies of ALK-Rearranged NSCLC: ALK- and BRAF-Mutations Followed by Epithelial-Mesenchymal Transition
por: Urbanska, Edyta M., et al.
Publicado: (2020)

The Landscape of Immunotherapy Resistance in NSCLC
por: Frisone, Daniele, et al.
Publicado: (2022)

Editorial: Immunotherapy for NSCLC with oncogenic driver variants
por: Du, Yijia, et al.
Publicado: (2022)

Clinical, Conventional CT and Radiomic Feature-Based Machine Learning Models for Predicting ALK Rearrangement Status in Lung Adenocarcinoma Patients
por: Song, Lan, et al.
Publicado: (2020)

Focus on Alectinib and Competitor Compounds for Second-Line Therapy in ALK-Rearranged NSCLC
por: Tran, Phu N., et al.
Publicado: (2016)

The Impact of Comprehensive Genomic Profiling (CGP) on the Decision-Making Process in the Treatment of ALK-Rearranged Advanced Non-Small Cell Lung Cancer (aNSCLC) After Failure of 2(nd)/3(rd)-Generation ALK Tyrosine Kinase Inhibitors (TKIs)
por: Raphael, Ari, et al.
Publicado: (2022)

ALK inhibitors in ALK-rearranged non-small cell lung cancer with and without brain metastases: systematic review and network meta-analysis
por: Jiang, Jun, et al.
Publicado: (2022)

Recent Advances in Immunotherapy in Metastatic NSCLC
por: Bansal, Pranshu, et al.
Publicado: (2016)

Erratum: The landscape of immunotherapy resistance in NSCLC
Publicado: (2023)

The Resistance Mechanisms and Treatment Strategies for ALK-Rearranged Non-Small Cell Lung Cancer
por: Pan, Yue, et al.
Publicado: (2021)

Immunotherapy for ALK-Rearranged Non-Small Cell Lung Cancer: Challenges Inform Promising Approaches
por: Sankar, Kamya, et al.
Publicado: (2021)

STK3-ALK, a Novel ALK Rearrangement in Non-Small Cell Lung Cancer With Sensitivity to Tyrosine Kinase Inhibitors: A Case Report
por: Feng, Chunlai, et al.
Publicado: (2021)

Crizotinib efficacy in advanced non-squamous NSCLC patients with ALK or ROS1 rearrangement
por: Krawczyk, Paweł, et al.
Publicado: (2021)

Anti-Angiogenic Therapy in ALK Rearranged Non-Small Cell Lung Cancer (NSCLC)
por: Tan, Aaron C., et al.
Publicado: (2022)

Case Report: A Pregnant Woman Diagnosed as ALK-Rearrangement Lung Large Cell Neuroendocrine Cancer With Brain Metastasis
por: Fu, Zaixiang, et al.
Publicado: (2022)

Immunotherapy in NSCLC Patients With Brain and Leptomeningeal Metastases
por: Pierret, Thomas, et al.
Publicado: (2022)

The Impact of Clinical Factors, ALK Fusion Variants, and BIM Polymorphism on Crizotinib-Treated Advanced EML4–ALK Rearranged Non-small Cell Lung Cancer
por: Lin, Yen-Ting, et al.
Publicado: (2019)

Durable Clinical Response to ALK Tyrosine Kinase Inhibitors in Epithelioid Inflammatory Myofibroblastic Sarcoma Harboring PRRC2B-ALK Rearrangement: A Case Report
por: Wang, Zhan, et al.
Publicado: (2022)

Evaluation of Efficacy of ALK Inhibitors According to Body Mass Index in ALK Rearranged NSCLC Patients—A Retrospective Observational Study
por: Siringo, Marco, et al.
Publicado: (2023)

Current Status of Immune Checkpoint Inhibitor Immunotherapy for Lung Cancer
por: Xiong, Wei, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_tds31jc4tp57m6t2chj6sje9gc